Scholar Rock (SRRK)

Scholar Rock Holding Corporation remains a Strong Buy despite a recent FDA Complete Response Letter for apitegromab in spinal muscular atrophy. The CRL was due to manufacturing site issues with Catale...

The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA)...

Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant.

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Tuesday.

The U.S. Food and Drug Administration has declined to approve Scholar Rock's drug for a rare neuromuscular disease, citing issues at a third party manufacturing facility, the company said on Tuesday.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM...

Monday was a good day to be invested in Scholar Rock (SRRK 6.31%) stock. The clinical-stage biotech received a nod from an analyst initiating coverage on its shares, a move that sent its price more th...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscula...

Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Boa...